HIV Medicine

Hyaluronic acid treatment of facial fat atrophy in HIV-positive patients
pp. 475-482(8)
Authors: Bugge, H; Negaard, A; Skeie, L; Bergersen, B

Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy
pp. 483-490(8)
Authors: Curkendall, SM; Richardson, JT; Emons, MF; Fisher, AE; Everhard, F

Hepatitis C is associated with type 2 diabetes mellitus in HIV-infected persons without traditional risk factors
pp. 491-497(7)
Authors: Jain, MK; Aragaki, C; Fischbach, L; Gibson, S; Arora, R; May, L; Vardhineni, K; Lee, WM

Validation of three-dimensional laser scanning for the assessment of facial fat changes
pp. 498-503(6)
Authors: Paton, NI; Yang, Y; Sitoh, Y-Y; Oo Tha, Naing

Presence of M184I/V in minor HIV-1 populations of patients with lamivudine and/or didanosine treatment failure
pp. 504-510(7)
Authors: Svedhem, V; Bergroth, T; Lidman, K; Sönnerborg, A

Impact of transmission of drug-resistant HIV on the course of infection and the treatment success. Data from the German HIV-1 Seroconverter Study
pp. 511-519(9)
Authors: Poggensee, G; Kücherer, C; Werning, J; Somogyi, S; Bieniek, B; Dupke, S; Jessen, H; Hamouda, O

Improved cognitive function as a consequence of hepatitis C virus treatment
pp. 520-528(9)
Authors: Thein, HH; Maruff, P; Krahn, MD; Kaldor, JM; Koorey, DJ; Brew, BJ; Dore, GJ

Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors
pp. 529-535(7)
Authors: Chetchotisakd, P; Anunnatsiri, S; Mootsikapun, P; Kiertiburanakul, S; Anekthananon, T; Bowonwatanuwong, C; Kowadisaiburana, B; Supparatpinyo, K; Ruxrungtham, K

HIV in the UK 1980-2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy
pp. 536-546(11)
Authors: Phillips, AN; Sabin, C; Pillay, D; Lundgren, JD

Trends and determinants of severe morbidity in HIV-infected patients: the ANRS CO3 Aquitaine Cohort, 2000-2004
pp. 547-554(8)
Authors: Bonnet, F; Chêne, G; Thiébaut, R; Dupon, M; Lawson-Ayayi, S; Pellegrin, JL; Dabis, F; Morlat, P

Peripheral arterial disease in HIV-infected and uninfected women
pp. 555-560(6)
Authors: Sharma, A; Holman, S; Pitts, R; Minkoff, H L; DeHovitz, JA; Lazar, J

Impact of GB virus type C infection on mother-to-child HIV transmission in the Women and Infants Transmission Study Cohort
pp. 561-567(7)
Authors: Handelsman, E; Cheng, I; Thompson, B; Hershow, R; Mofenson, LM; Hollinger, FB; Chen, KT; Burchett, SK; Klinzman, D; Stapleton, JT

Hill A, Moyle G. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. HIV Med 2007; 8: 259-264: Methodological accuracy in cross-trial comparisons of antiretroviral regimens in multitreated patients
pp. 568-570(3)
Authors: Llibre, JM; Pérez-Alvarez, N

Relative antiviral efficacy should not be inferred from cross-trial comparisons
pp. 570-571(2)
Author: Hall, D

Authors' Reply to Drs JM Llibre, N Pérez-Alvarez & D Hall
pp. 571-572(2)
Authors: Hill, A; Moyle, G

Vanishing bile duct syndrome in a patient with advanced AIDS. HIV Med 2007; 8: 70-72
pp. 573-574(2)
Authors: Aldeen, T; Davies, S

A note of thanks to referees for Volume 8, 2007
pp. 575-576(2)